Skip to main content
Uncategorized

More than twenty Catalan biotechnology and pharmaceutical companies participate in BIO-Europe 2012

By 13 de November de 2012November 18th, 2020No Comments
< Back to news
Biocat booth in the exhibition area, BIO-Europe Hamburg (Germany). Source: Biocat.
 13.11.2012

More than twenty Catalan biotechnology and pharmaceutical companies participate in BIO-Europe 2012

A total of 22 Catalan companies are participating today through Wednesday in the eighteenth edition of BIO-Europe, the top European meeting of the biotechnology industry that was inaugurated this morning in Hamburg (Germany). Biocat, which is a Gold Sponsor for this year's event, has a booth (N. 20) in the exhibit area to support Catalan business representatives, a group that makes up 40% of the Spanish companies participating.


Biocat is holding one of the International Seminars that, under the title Catalonia: building a competitive hub, will present the Catalan biocluster, one of the most dynamic in Spain and one of the most active areas in southern Europe in this field. Over the past five years, the rate at which new biotechnology companies have been created has oscillated between 30% and 15% on average, with a total of 481 companies in 2012.

During this event, moderated by Biocat Head of Communications and External Relations Adela Farré, four examples of noteworthy companies will be presented, giving a general overview of the best business practices that are contributing to the sector’s competitiveness and innovation:

– AB-Biotics, the only Catalan biotech firm traded on the Alternative Stock Market (MAB) and which is devoted to developing biomarkers and nutraceutics, highlighting a chip that measures a patient’s predisposition to respond to the most commonly used drugs to treat depression, schizophrenia, epilepsy and bipolar disorders;

– University Institute of Science and Technology (IUCT), a high-technology company that creates and develops products for the chemical, pharmaceutical and biotechnology industries and has created a seed-capital fund to invest in biotechnology start-ups and boost their growth;

– Ysios Capital Partners, the first venture capital investment fund specializing in biotech in Spain;

– Almirall, one of the largest Catalan pharmaceutical companies, which carries out biotechnology collaboration and investment projects.